Last reviewed · How we verify
COVID-HIG
COVID-HIG is a Biologic drug developed by Emergent BioSolutions. It is currently in Phase 1 development. Also known as: NP-028.
At a glance
| Generic name | COVID-HIG |
|---|---|
| Also known as | NP-028 |
| Sponsor | Emergent BioSolutions |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults (PHASE1)
- Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-HIG CI brief — competitive landscape report
- COVID-HIG updates RSS · CI watch RSS
- Emergent BioSolutions portfolio CI
Frequently asked questions about COVID-HIG
What is COVID-HIG?
COVID-HIG is a Biologic drug developed by Emergent BioSolutions.
Who makes COVID-HIG?
COVID-HIG is developed by Emergent BioSolutions (see full Emergent BioSolutions pipeline at /company/emergent-biosolutions).
Is COVID-HIG also known as anything else?
COVID-HIG is also known as NP-028.
What development phase is COVID-HIG in?
COVID-HIG is in Phase 1.
Related
- Manufacturer: Emergent BioSolutions — full pipeline
- Also known as: NP-028
- Compare: COVID-HIG vs similar drugs
- Pricing: COVID-HIG cost, discount & access